TCR2 Therapeutics to Debut Positive Solid Tumor Data on its Novel TRuC™ Engineered T Cell Platform at the World Preclinical Congress

CAMBRIDGE, Mass., June 7, 2017 /PRNewswire/ -- TCR² Therapeutics Inc. announced today that it will present preclinical data from two of its TRuC™ engineered T cell programs at the World Preclinical Congress (WPC) being held June 12-16 in Boston.

Oral Presentation Title: TRuC™-T Cells: A Novel Kind of Engineered T Cells for Solid Tumors Exploiting the Signaling Power of the Complete T Cell Receptor
Session Title: Advances in Targeting Agonists and the TCR Complex
Date & Time: Tuesday June 13, 2017 from 2:20-2:50pm EDT
Presenter: Robert Hofmeister, PhD, Chief Scientific Officer at TCR² Therapeutics

The abstract is available on WPC's website at:
http://www.worldpreclinicalcongress.com/Cancer-Immunotherapy-Combinations/

About TCR² Therapeutics
TCR² Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies that utilize the full signaling power of complete T cell receptors (TCR). TCR² has developed a unique proprietary TRuC™ platform which can reprogram the natural TCR complex to recognize specific antigens found on tumors where they elicit rapid killing of cancer cells. The company has demonstrated superior activity against both hematological and solid tumor targets in preclinical models compared to CAR-T and believes its TRuC™-reprogrammed T cells will serve as a backbone for solid tumor therapies. TCR² was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA. For more information, please visit www.tcr2.com.

SOURCE TCR2 Therapeutics

Related Links

http://www.tcr2.com